A Phase 1B trial is underway to test the effectiveness of CK-2127107 for older adults who face muscular weakness or fatigue related to chronic diseases like COPD.

CK-2127107 is a next-generation fast skeletal muscle troponin activator (FSTA) that is being developed in collaboration between Cytokinetics and Astellas.

CK-2127107 is able to slow the rate of calcium release from the regulatory troponin complex of skeletal muscle fibers, ultimately leading to an increase in the skeletal muscles’ ability to contract.

CK-2127107 has already been granted orphan drug designation by the FDA for the potential treatment of spinal muscular atrophy (SMA).

Read more at www.copdnewstoday.com